Positive results from Niemann Pick Type C clinical trial – Ataxia

Positive results from Niemann Pick Type C clinical trial

Positive results from Niemann Pick Type C clinical trial

On 30 September, IntraBio announced positive results from their multinational clinical trial testing IB1001 in Niemann Pick Type C (NPC). NPC is a rare lysosomal storage disorder, which has ataxia as a symptom. IB1001 resulted in a clinically meaningful improvement of symptoms, including in the Scale for the Assessment and Rating of Ataxia (SARA) score. The treatment was observed to be safe and well-tolerated, with no drug-related serious adverse events. The trial took place in the USA, European Union and the UK.

IntraBio are currently testing IB1001 in a clinical trial for other neurological conditions, including ataxia-telangiectasia, and are planning trials in other neurodegenerative conditions.

“The positive outcome of the IB1001-201 clinical trial is an important step in bringing this promising treatment to patients as quickly as possible,” said Taylor Fields, Senior Vice-President, IntraBio.

Read the full press release on the IntraBio website and Accesswire.

Posted on 01/10/2020


Something went wrong. Please check your entries and try again.
fundraise image


Take part in a challenge or create your fundraiser. Every penny you raise will help those affected by ataxia.

Donate Image


To make either a one off or recurring donation which will help fund research into treatments and cures and supports those affected ataxia

Volunteer Image


Support the ataxia community and volunteer with Ataxia UK. From social media to telephone befriending, there are loads of ways you can make a difference to someone's life.

Donate Now
Welcome to our new site! We hope you like it.
As it's brand new, there may be a few temporary glitches such as broken links - we are working on getting these all fixed ASAP. If you'd like to give us any feedback or let us know if something isn't quite right, please email website@ataxia.org.uk
Scroll to Top